Biostage Inc (NASDAQ:BSTG) has been given a $3.00 target price by Maxim Group in a research note issued on Friday. The brokerage currently has a a “buy” rating on the stock. Maxim Group’s target price suggests a potential upside of 172.73% from the company’s current price.

Shares of Biostage (NASDAQ:BSTG) traded down 13.455% during trading on Friday, hitting $0.952. The stock had a trading volume of 349,798 shares. The stock’s market cap is $16.29 million. The stock’s 50-day moving average price is $1.05 and its 200 day moving average price is $1.36. Biostage has a one year low of $0.53 and a one year high of $3.47.

Biostage (NASDAQ:BSTG) last posted its quarterly earnings results on Thursday, August 11th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.04. On average, equities analysts forecast that Biostage will post ($0.86) EPS for the current year.

About Biostage

Biostage, Inc, formerly Harvard Apparatus Regenerative Technology, Inc, is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient’s own cells.

5 Day Chart for NASDAQ:BSTG

Receive News & Stock Ratings for Biostage Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostage Inc and related stocks with our FREE daily email newsletter.